LONGEFI
mTOR4 min readSignal45·Moderate

Selective mTOR inhibitor begins Phase 2 in adults over 65

Original source
ClinicalTrials.gov
Published
2 Aug 2026
Category
mTOR
LONGEFI analysisQuick take

Rapamycin-like drugs extend life in animals more reliably than anything else, but human trials in this mechanism have failed before. A new trial is trying again with a more selective drug and older participants. It is a rerun of a hard question, not a breakthrough.

What happened

Source factsAs reported by ClinicalTrials.gov

The trial will enrol approximately 480 adults aged 65+ across 30 sites.

The primary endpoint is laboratory-confirmed respiratory infection incidence over 16 weeks.

The compound is designed to inhibit TORC1 selectively, avoiding TORC2-related metabolic effects.

Why it matters

LONGEFI analysisLONGEFI interpretation, not source reporting

mTOR is the most reproducible lifespan mechanism in animals, so repeated human failure is one of the field's most important unresolved discrepancies.

Infection incidence is a hard, objective endpoint — a stronger design choice than self-reported outcomes.

A positive result would be the first robust human demonstration that an aging pathway intervention improves a clinical outcome.

Evidence check

Optional scientific context: how much weight this finding can carry.

Source factsStudy characteristics as reported in the primary source
Study
Study type
Randomised Phase 2 trial (enrolling)
Model
Humans
Participants
Planned n ≈ 480
Study phase
Phase 2
Control group
Yes — randomised, placebo-controlled (enrolling)
Peer reviewed
No — preprint or registry
Evidence quality
Replication
Prior programme in the same mechanism failed its pivotal endpoint
Limitations
  • No results yet — this is a trial start, not a readout.
  • Registry entries are not peer reviewed.
  • Respiratory infection incidence is season-dependent and noisy.
  • Selectivity claims are based on preclinical data.
LONGEFI analysisLONGEFI evidence rating
EvidenceEarly

LONGEFI Signal

LONGEFI's deterministic scientific synthesis — not a market view.

LONGEFI SignalLONGEFI Signal is a 0–100 comparison score built from four analytical dimensions — scientific evidence, novelty, human relevance and market relevance — so developments can be ranked against each other. NOT AN INVESTMENT RATING: it is not a prediction of investment performance and not a view on any security.
45·Moderate
Scientific evidence30

How strong the underlying evidence is.

Novelty41

How new or meaningfully different the finding is.

Human relevance63

How close the evidence is to meaningful human application.

Market relevance44

How likely this is to matter commercially or strategically.

LONGEFI Signal is a 0–100 comparison score across scientific evidence, novelty, human relevance and market relevance. It is not an investment rating and not a prediction of investment performance.LONGEFI Signal is a 0–100 comparison score built from four analytical dimensions — scientific evidence, novelty, human relevance and market relevance — so developments can be ranked against each other. NOT AN INVESTMENT RATING: it is not a prediction of investment performance and not a view on any security.

Science explained

The terminology, in plain language.

mTOR
A cellular switch that decides between growth and repair. Dialling it down promotes repair.
TORC1 vs TORC2
Two complexes mTOR forms. Most benefits are attributed to blocking the first; most side effects to blocking the second.
Rapalog
A drug chemically related to rapamycin, the original mTOR inhibitor.
Pivotal endpoint
The result a trial must hit for regulators to consider approval.

What would change our view?

The findings that would raise or lower this Signal.

LONGEFI analysisLONGEFI assessment of open questions
Would strengthen

Positive interim

A pre-specified interim showing separation on clinical infection endpoints.

Would weaken

Repeat failure

A second pivotal-scale miss on the same endpoint class.

Would weaken

Tolerability dropout

Discontinuation rates undermining chronic dosing in older adults.

Sources & traceability

Supporting documents, underlying datasets and independent sources are not the same thing.

ScienceMarkets

Everything below is commercial interpretation. It does not form part of the LONGEFI Scientific Signal.

Companies & assets

Exposure to the technology discussed, not an investment view.

Tornado Therapeutics

Private

This development may be relevant to this company’s longevity programs.

mTOR inhibition / immune aging

Selective mTOR inhibition can capture rapamycin's benefits without broad immunosuppression.

Market implications

Which parts of the field this touches, and over what horizon.

LONGEFI analysisLONGEFI mapping — no buy, sell or hold recommendations
Horizon
Long-term
Market relevance
Low
Evidence
Early

  • Tornado Therapeutics

    Too early to assess

    Selective mTOR inhibition in age-related immune decline.

    A trial start is not evidence. The prior pivotal failure remains the dominant fact until data reads out.

Technologies affected
  • Selective TORC1 inhibition
  • Rapalogs
  • Immune aging biomarkers
Industries affected
  • Biotechnology
  • Immunology
  • Geroscience trials

Low immediate relevance. Trial initiations are not evidence. The category carries elevated risk given a prior pivotal failure in the same mechanism.

LONGEFI does not issue buy, sell or hold recommendations, and nothing here is personalized financial advice.

Trend connections

How this connects to themes LONGEFI tracks over time.

mTORImmunology